Speaker: Sara Mariotto, MD PhD, Neurology Unit, University of Verona
What key insights will you be sharing in your session and why is this important?
Sara Mariotto: Good morning, everyone. I'm Sara Mariotto from the University of Verona, Italy, and in this session we will discuss which assay is the best to test the MOG antibodies, which matrix we should test them in and which is the best moment to test them during the clinical evolution of the disease in every patient. This is, of course, very important because it provides the best data on the MOG antibodies results, which is mandatory to diagnose MOGAD and for a proper differential diagnosis with other inflammatory or demyelinating conditions. So let's join us.
Why is ECTRIMS 2024 a must-attend event for the MS and neurological research community?
Sara Mariotto: At ECTRIMS, we will discuss different topics related to MS and other related neuroimmunological conditions like Neuromyelitis Optica and MOGAD, discussing the clinical aspects of the utility of biofluid markers. And we can really do a good networking so it's relevant to join.
